AMAG Pharmaceuticals Announces Availability of 2020 Grants to Support Research Aimed at Improving the Health of Mothers and Neonates
AMAG Pharmaceuticals, Inc. is committed to funding research aimed at reducing the risk of premature birth and preeclampsia in order to improve the health of neonates and infants in the United States through its Prematurity and Preeclampsia Research Grants Program.
AMAG Pharmaceuticals awarded nearly $300,000 in research grants in 2019 to the following principal investigators to support the important research they are conducting focused on prematurity prevention:
- Jaipal Singh, Ph.D., Director at Indiana Center for Biomedical Innovation at Indiana University School of Medicine and Jennifer Sasser, Ph.D., Associate Professor at the University of Mississippi Medical Center are both researching pharmacological and molecular validation of dimethylarginine dimethylaminohydrolase as a therapeutic target for preeclampsia;
- Rupsa C. Boelig, M.D., M.S. Assistant Professor Department of Obstetrics and Gynecology, Division of Maternal and Fetal Medicine, Walter K. Kraft, M.D. Professor, Department of Pharmacology and Experimental Therapeutics, Leonard Edelstein, Ph.D. Assistant Professor, Department of Medicine all of Thomas Jefferson University are researching aspirin for prevention of preeclampsia: individual determinants of platelet response and pregnancy outcomes;
- Jennifer Condon, Ph.D., Associate Professor with Tenure in collaboration with Gil Mor, M.D., Ph.D., Scientific Director, C.S. Mott Center for Human Growth and Development, Vice Chair of Research John M. Malone Jr., M.D. Endowed Professor, Department of Obstetrics and Gynecology Wayne State University School of Medicine both are researching targeting circulating GRP78 as a novel agent to prevent preterm labor;
- Anum Minhas M.D., Cardiology Fellow, Allison Hays, M.D., Associate Professor of Medicine, Arthur Vaught, M.D., Assistant Professor of Gynecology and Obstetrics and Sammy Zakaria, M.D., MPH, Assistant Professor of Medicine, Division of Cardiology Department of Medicine all of Johns Hopkins Medicine will be researching novel imaging methods to understand the association of preeclampsia and cardiovascular disease.
The company is pleased to announce that it will be funding research grants in prematurity and preeclampsia in 2020 for a total of $250,000. Consideration will be given to basic or clinical research in maternal, fetal and neonatal/infant health. All proposals will be evaluated and the final awards will be determined based on scientific merit by an external review panel comprised of experts in the field. The panel will determine allocation of these funds, with no single recipient receiving more than $50,000 to allow for multiple grants to be provided.*
Interested researchers should complete an application and submit by June 30, 2020 to: annual.prematurity.preeclampsia.grants@amagpharma.com
Research awards are expected to be announced by September 30, 2020 with funds to be provided upon execution of a research grant contract, to ensure compliance with applicable regulations.
Download the 2020 AMAG Research Grant Application Form here.
*The funds from this grant program should be used exclusively for the research program and are not to be designated as general overhead. The purpose of any grant approved is to provide financial support consistent with any applicable federal and state laws and regulations, for charitable, scientific or educational purposes only, and is not contingent on the purchase or recommendation of any AMAG products, nor is it intended to induce the purchase or recommendation of AMAG products.
